Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Herbalife Nutrition Ltd (HLF) Price & Performance

ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.

Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.

Herbalife (HLF) trades at $13.14, showing modest daily gains of 0.23%. The stock presents a mixed technical picture with neutral signals from oscillators and bearish moving averages. Fundamentally, HLF maintains strong gross margins of 77.78% and attractive valuation metrics including a P/E of 5.64 and P/S of 0.26. Recent Q1 2026 earnings beat expectations with $0.64 EPS versus $0.607 expected, while the company completed a significant $1.45 billion debt refinancing in April 2026 to strengthen its balance sheet.

HLF offers value investment appeal with deep discount valuations and improving debt trends, though negative shareholder equity and competitive pressures in the nutrition space present ongoing challenges. Analyst sentiment leans bullish with 57.7% buy ratings, but the stock faces headwinds from its multi-level marketing model scrutiny and regional market volatility. The upcoming Q2 2026 earnings on August 5 will be crucial for validating recent guidance increases.